CN115153029A - 一种具有降低血脂和体脂功能的益生菌菌群组合物 - Google Patents
一种具有降低血脂和体脂功能的益生菌菌群组合物 Download PDFInfo
- Publication number
- CN115153029A CN115153029A CN202210958232.2A CN202210958232A CN115153029A CN 115153029 A CN115153029 A CN 115153029A CN 202210958232 A CN202210958232 A CN 202210958232A CN 115153029 A CN115153029 A CN 115153029A
- Authority
- CN
- China
- Prior art keywords
- powder
- controlling
- parts
- drying
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 133
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 133
- 241000894006 Bacteria Species 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 63
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 38
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 239000008280 blood Substances 0.000 title claims abstract description 38
- 239000000843 powder Substances 0.000 claims abstract description 103
- 230000001580 bacterial effect Effects 0.000 claims abstract description 61
- 229920002472 Starch Polymers 0.000 claims abstract description 34
- 235000019698 starch Nutrition 0.000 claims abstract description 34
- 239000008107 starch Substances 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 32
- 238000004108 freeze drying Methods 0.000 claims abstract description 31
- 239000003223 protective agent Substances 0.000 claims abstract description 31
- 239000003094 microcapsule Substances 0.000 claims abstract description 25
- 239000004005 microsphere Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000003607 modifier Substances 0.000 claims abstract description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 6
- 102000011632 Caseins Human genes 0.000 claims abstract description 6
- 108010076119 Caseins Proteins 0.000 claims abstract description 6
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229940080237 sodium caseinate Drugs 0.000 claims abstract description 6
- 235000010957 calcium stearoyl-2-lactylate Nutrition 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 96
- 238000003756 stirring Methods 0.000 claims description 55
- 238000002360 preparation method Methods 0.000 claims description 46
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- 238000000855 fermentation Methods 0.000 claims description 35
- 230000004151 fermentation Effects 0.000 claims description 35
- 238000011081 inoculation Methods 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 34
- 238000001694 spray drying Methods 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 24
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 21
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 21
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 21
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 21
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 21
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 20
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 20
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 20
- 229920002774 Maltodextrin Polymers 0.000 claims description 20
- 239000005913 Maltodextrin Substances 0.000 claims description 20
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 20
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 20
- 229910021641 deionized water Inorganic materials 0.000 claims description 20
- 239000008103 glucose Substances 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 20
- 238000009630 liquid culture Methods 0.000 claims description 20
- 229940035034 maltodextrin Drugs 0.000 claims description 20
- 239000011812 mixed powder Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 230000010355 oscillation Effects 0.000 claims description 19
- 238000000498 ball milling Methods 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 150000004676 glycans Chemical class 0.000 claims description 15
- 229920001282 polysaccharide Polymers 0.000 claims description 15
- 239000005017 polysaccharide Substances 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 14
- 229930182490 saponin Natural products 0.000 claims description 14
- 150000007949 saponins Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 11
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 10
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 claims description 10
- 229920002261 Corn starch Polymers 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 241000195633 Dunaliella salina Species 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 229920002581 Glucomannan Polymers 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 229920000161 Locust bean gum Polymers 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- 229920000881 Modified starch Polymers 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 10
- 235000010489 acacia gum Nutrition 0.000 claims description 10
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 10
- 239000008120 corn starch Substances 0.000 claims description 10
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 229940046240 glucomannan Drugs 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 235000010420 locust bean gum Nutrition 0.000 claims description 10
- 239000000711 locust bean gum Substances 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 10
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 10
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 10
- 239000010802 sludge Substances 0.000 claims description 10
- 235000010413 sodium alginate Nutrition 0.000 claims description 10
- 239000000661 sodium alginate Substances 0.000 claims description 10
- 229940005550 sodium alginate Drugs 0.000 claims description 10
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 claims description 10
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 10
- 239000012137 tryptone Substances 0.000 claims description 10
- ZTOKUMPYMPKCFX-CZNUEWPDSA-N (E)-17-[(2R,3R,4S,5S,6R)-6-(acetyloxymethyl)-3-[(2S,3R,4S,5S,6R)-6-(acetyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxyoctadec-9-enoic acid Chemical compound OC(=O)CCCCCCC/C=C/CCCCCCC(C)O[C@@H]1O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(C)=O)O1 ZTOKUMPYMPKCFX-CZNUEWPDSA-N 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 239000007791 liquid phase Substances 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000002715 modification method Methods 0.000 claims description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 238000009423 ventilation Methods 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 16
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 5
- 208000003455 anaphylaxis Diseases 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 229940083466 soybean lecithin Drugs 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001276 controlling effect Effects 0.000 description 86
- 210000002966 serum Anatomy 0.000 description 26
- 108010023302 HDL Cholesterol Proteins 0.000 description 15
- 108010028554 LDL Cholesterol Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 241001122767 Theaceae Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000000265 homogenisation Methods 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 238000010241 blood sampling Methods 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 4
- 229940024171 alpha-amylase Drugs 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 4
- -1 starch Chemical class 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028744 lysogeny Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000020925 non fasting Nutrition 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000756943 Codonopsis Species 0.000 description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 description 2
- 240000000171 Crataegus monogyna Species 0.000 description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000021238 nutrient digestion Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A23L29/04—Fatty acids or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/05—Organic compounds containing phosphorus as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
Abstract
本发明公开了一种具有降低血脂和体脂功能的益生菌菌群组合物,属于益生菌菌群组合物技术领域,所述益生菌菌群组合物,按重量份计,由以下成分组成:75‑80份改性菌粉,10‑12份中药微胶囊,3‑5份冻干保护剂,6‑8份改性剂;所述改性剂的组成,按重量份计,由以下成分组成:5‑7份淀粉微球,1‑2份酪蛋白酸钠,0.5‑0.8份大豆磷脂,0.1‑0.3份硬脂酰乳酸钙;本发明的益生菌菌群组合物能够在提高降脂效果及降低益生菌的过敏反应的同时,避免对益生菌活性的影响,降低益生菌在使用中对肠道的刺激,同时还能够避免产生依赖性。
Description
技术领域
本发明涉及益生菌菌群组合物技术领域,具体涉及一种具有降低血脂和体脂功能的益生菌菌群组合物。
背景技术
随着社会经济的发展和人们生活方式的改变,肥胖已成为一种潜在的健康杀手,严重威胁着人类的健康。椐WHO估计,目前全球肥胖症患者超过4亿,而超重人群已达到16亿,每年至少有260万人因肥胖症而死亡。肥胖是一种多因素影响的慢性代谢性疾病,是由于能量摄入过多而无法完全消耗,引发身体脂肪沉积过多的现象。超重和肥胖是诱发糖尿病、高血压、心血管疾病、癌症和睡眠呼吸障碍等很多疾病的关键因素,目前治疗肥胖和相关疾病的一个重要目标为营养消化和吸收抑制剂的发展。
在人类消化系统中膳食脂肪的消化主要靠胰腺脂肪酶,它能够将人体摄入的三酰基甘油酯水解40-70%;而人体摄入的碳水化合物则主要通过α-淀粉酶和α-糖苷酶来水解,因此,抑制胰脂肪酶、α-淀粉酶的活性,降低脂质和碳水化合物的吸收是开发治疗肥胖药物的一个极具吸引力的方法。脂肪酶失去活性则不能将食物中的脂肪分解为可以被人体吸收的游离脂肪酸和甘油,从而减少脂肪摄入,发挥降低血脂和体脂的作用,体内唾液和肠道α-淀粉酶失活,则能够降低淀粉等碳水化合物的分解消化,从而控制体重增长,减缓脂肪蓄积。
益生菌是通过定植在人体内,改变宿主某一部位菌群组成的一类对宿主有益的活性微生物,通过调节宿主黏膜与系统免疫功能或通过调节肠道内菌群平衡,促进营养吸收保持肠道健康的作用,从而产生有利于健康作用的单微生物或组成明确的混合微生物。研究发现,益生菌能够抑制胰脂肪酶、α-淀粉酶的活性,降低脂质和碳水化合物的吸收,因此,越来越多的人使用益生菌来降低血脂和体脂,但是益生菌在使用中存在以下缺点:见效慢,易反弹;服用益生菌后后会可能会产生过敏反应;对于肠道菌群原本就严重失衡的人群,在服用益生菌的一段时间内可能出现腹痛、腹泻、轻微腹胀等不适;在益生菌使用的过程中会产生胺类物质,可能引发机体的免疫反应,引起皮肤过敏。
现有技术中,虽然可以通过使用中药和益生菌复配,来提高益生菌的降脂效果,降低过敏反应,但是中药会影响益生菌的活性,从而影响了益生菌的使用效果;而且中药和益生菌复配后,并不能降低益生菌使用中产生的胺类物质引起的皮肤过敏现象,还会在使用中产生依赖性,一旦停用,容易造成血脂和体脂的再次升高,因此,研发一种具有降低血脂和体脂功能的益生菌菌群组合物,能够在提高降脂效果及降低益生菌的过敏反应的同时,避免对益生菌活性的影响,降低益生菌使用中产生的胺类物质引起的皮肤过敏现象,同时还能够避免产生依赖性,是目前急需解决的问题。
中国专利CN105030950B公开了一种防治高血脂的微生态制剂及其制备方法和应用,该制剂组合物包括纳豆冻干粉、益生菌和药食同源中药,按重量份计具体由以下组分组成:纳豆冻干粉20-40份,山楂15-40份,银杏18-35份,香菇5-25份;所述益生菌为植物乳杆菌、罗伊氏乳杆菌和青春双歧杆菌中的一种或多种;该发明制备的微生态制剂对高血脂有预防及辅助治疗的作用,在防治高血脂的同时还可调节肠道菌群平衡,提高抵抗力,但是加入的山楂、银杏会对益生菌的活性产生影响,还容易产生依赖性。
发明内容
针对现有技术存在的不足,本发明提供了一种具有降低血脂和体脂功能的益生菌菌群组合物,能够在提高降脂效果及降低益生菌的过敏反应的同时,避免对益生菌活性的影响,降低益生菌使用中产生的胺类物质引起的皮肤过敏现象,同时还能够避免产生依赖性。
为解决以上技术问题,本发明采取的技术方案如下:
一种具有降低血脂和体脂功能的益生菌菌群组合物,按重量份计,由以下成分组成:75-80份改性菌粉,10-12份中药微胶囊,3-5份冻干保护剂,6-8份改性剂。
所述改性菌粉的制备方法,由以下步骤组成:制备种子液、制备发酵液、干燥、改性;
所述制备种子液的方法为:分别将冷冻保存的植物乳杆菌、鼠李糖乳杆菌、副干酪乳杆菌、动物双歧杆菌、两歧双歧杆菌、罗伊氏乳杆菌在固体LB平板上划线进行活化,然后分别从LB平板中挑选单菌落接种于装有100mL液体培养基的250mL锥形瓶中,将250mL锥形瓶放入摇床进行摇床培养,控制摇床培养的温度为36-38℃,转速为220-240rpm,时间为12-14h,摇床培养结束后分别得到植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液;
所述液体培养基,由以下成分组成:3-4g/L葡萄糖,2-3g/L胰蛋白胨,0.5-0.7g/L红糖,0.3-0.5g/L磷酸氢二钠,0.2-0.4g/L磷酸二氢钠,剩余为去离子水。
所述制备发酵液的方法为:分别将植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液依次接种于同一MRS液体培养基中,控制植物乳杆菌的接种量为1-1.5%,鼠李糖乳杆菌的接种量为1.5-2%,副干酪乳杆菌的接种量为1.5-2%,动物双歧杆菌的接种量为2-2.5%,两歧双歧杆菌的接种量为2-2.5%,罗伊氏乳杆菌的接种量为0.5-1%,接种完成后进行搅拌发酵培养,控制搅拌发酵培养的温度为36-38℃,转速为320-340rpm,通气量为1.5-1.7vvm,时间为18-20h,搅拌发酵培养结束得到发酵液;
所述MRS液体培养基,由以下成分组成:4-6g/L胰蛋白胨,5-7g/L葡萄糖,4-5g/L酵母膏,1.5-2g/L牛肉膏,1-1.2g/L吐温80,0.8-1g/L磷酸氢二钾,0.3-0.5g/L硫酸镁,剩余为去离子水。
所述干燥的方法为:对发酵液进行离心分离,控制离心分离时的转速为2800-3000rpm,时间为5-6min,离心分离结束后得到的固相物作为菌泥,对菌泥进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-40℃至-35℃,真空度为400-500Pa,处理时间为50-55min,真空冷冻干燥结束得到菌粉。
所述改性的方法为:将菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖混合均匀后,得到初级改性菌粉,将初级改性菌粉置于反应容器内,将反应容器内的温度控制到15-20℃,搅拌速度控制到100-120rpm,将改性液雾化后通入反应容器内,控制雾化速度为140-150g/min,雾化结束后继续搅拌12-15min,然后进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-35℃至-30℃,真空度为300-400Pa,处理时间为30-35min,真空冷冻干燥结束得到改性菌粉;
所述改性中,菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖的重量比为80-85:5-7:2-4:3-6:2-5;
所述改性中,所述初级改性菌粉与改性液的重量比为100-105:3-5;
所述改性中,所述改性液的组成,按重量份计,包括:20-22份去离子水,1-3份氯化钠,1-1.5份大豆多糖,0.8-1份槐糖脂,0.5-0.8份硫酸锌;
所述改性菌粉中的益生菌的总数量为3.5×1010-4.0×1010cfu/g。
所述中药微胶囊的制备方法为:分别将白芷、连翘、黄芪、党参洗净后烘干,然后分别粉碎至200-300目,分别得到白芷粉、连翘粉、黄芪粉、党参粉,然后分别将白芷粉、连翘粉、黄芪粉、党参粉按照质量比为10-12:22-23:15-17:8-10混合均匀后得到混合中药粉,将混合中药粉与去离子水按照重量比为1:15-17混合均匀后进行超声破壁提取,控制超声破壁提取的声场频率为40-50kHz,声强为2.55W/cm2,提取时间为1.5-2h,提取结束得到中药提取液,将中药提取液进行离心分离,控制离心分离时的转速为3000-3200rpm,时间为6-7min,离心分离结束后得到的液相物作为滤液,将滤液、明胶、海藻酸钠混合后进行冷冻浓缩,控制冷冻浓缩的温度为-15℃至-10℃,时间为30-35min,冷冻浓缩结束得到浓缩液,向浓缩液中加入阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖,混合均匀后进行均质,控制均质的转速为4000-5000rpm,均质时间为5-6min,均质结束得到均质液,将均质液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为600-700Pa,进口温度为125-130℃,出口温度为65-70℃,真空喷雾干燥结束,得到中药微胶囊;
所述中药微胶囊的制备中,滤液、明胶、海藻酸钠的重量比为55-60:5-7:3-5;
所述中药微胶囊的制备中,浓缩液、阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖的重量比为50-55:3-5:2-4:4-6:1-2。
所述冻干保护剂的制备方法为:将预糊化淀粉、葡萄糖、麦芽糊精、乳糖混合均匀后,置于球磨机中进行球磨,控制球磨时的球料比为12-15:1,转速为280-300rpm,时间为40-45min,球磨结束得到混合粉,将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,控制电磁震荡处理的频率为130-150kHz,时间为4-5min,电磁震荡结束,得到冻干保护剂;
所述冻干保护剂的制备中,预糊化淀粉、葡萄糖、麦芽糊精、乳糖的重量比为15-18:3-5:4-6:2-3;
所述冻干保护剂的制备中,混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素的重量比为30-32:2-4:2-3:1-1.5。
所述改性剂的组成,按重量份计,由以下成分组成:5-7份淀粉微球,1-2份酪蛋白酸钠,0.5-0.8份大豆磷脂,0.1-0.3份硬脂酰乳酸钙;
所述淀粉微球的制备方法为:将玉米淀粉、环糊精、聚乙烯醇1788、海藻酸丙二醇酯、三偏磷酸钠加入去离子水中,将温度升高至50-55℃,然后开启搅拌并将搅拌速度控制到200-220rpm,搅拌30-35min后,停止搅拌,得到初级淀粉液,将初级淀粉液以3-4℃/min的速度降温至-20℃至-15℃,在-20℃至-15℃下静置17-20min,然后以1.5-2℃/min的速度升温至32-35℃,在32-35℃下进行以200-220rpm的搅拌速度搅拌15-20min,然后对初级淀粉液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为300-400Pa,进口温度为135-140℃,出口温度为70-75℃,真空喷雾干燥结束,得到淀粉微球;
所述淀粉微球的制备中,玉米淀粉、环糊精、聚乙烯醇1799、海藻酸丙二醇酯、三偏磷酸钠的重量比为20-22:2-4:1-3:2-5:2-4。
所述具有降低血脂和体脂功能的益生菌菌群组合物的制备方法为:将改性菌粉、中药微胶囊、冻干保护剂、改性剂混合均匀后进行真空冷冻干燥,控制真空冷冻干燥处理的温度为-35℃至-30℃,真空度为500-700Pa,处理时间为40-45min,真空冷冻干燥结束,得到降低血脂和体脂功能的益生菌菌群组合物。
与现有技术相比,本发明的有益效果为:
(1)本发明的具有降低血脂和体脂功能的益生菌菌群组合物,通过对菌粉进行改性,在冻干保护剂的制备中将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,以及在益生菌菌群组合物中加入改性剂,能够更好的发挥益生菌的降脂效果,在健康成年雄性sd大鼠上做实验,食用益生菌前的平均体重为428-431g,食用益生菌10d后的平均体重为352-359g,食用益生菌20d后的平均体重为320-325g,食用益生菌30d后的平均体重为316-320g;食用益生菌前血清TC为1.59-1.62mmol/L,食用益生菌前血清TG为1.15-1.19mmol/L,食用益生菌前血清LDL-C为0.26-0.29mmol/L,食用益生菌前血清HDL-C为0.83-0.87mmol/L,食用益生菌前脂体比为0.0168-0.0172;食用益生菌10d后血清TC为1.31-1.34mmol/L,食用益生菌10d后血清TG为0.76-0.79mmol/L,食用益生菌10d后血清LDL-C为0.17-0.19mmol/L,食用益生菌10d后血清HDL-C为1.07-1.09mmol/L,食用益生菌10d后脂体比为0.0142-0.0145;食用益生菌20d后血清TC为1.25-1.28mmol/L,食用益生菌20d后血清TG为0.59-0.62mmol/L,食用益生菌20d后血清LDL-C为0.16-0.18mmol/L,食用益生菌20d后血清HDL-C为1.10-1.13mmol/L,食用益生菌20d后脂体比为0.0136-0.0139;食用益生菌30d后血清TC为1.23-1.26mmol/L,食用益生菌30d后血清TG为0.58-0.60mmol/L,食用益生菌30d后血清LDL-C为0.16-0.17mmol/L,食用益生菌30d后血清HDL-C为1.12-1.14mmol/L,食用益生菌30d后脂体比为0.0132-0.0134;
(2)本发明的具有降低血脂和体脂功能的益生菌菌群组合物,通过对菌粉进行改性,以及在益生菌菌群组合物中加入改性剂,能够降低益生菌的过敏反应,同时降低益生菌使用中产生的胺类物质引起的皮肤过敏现象,在健康成年雄性sd大鼠上做实验,在食用益生菌10d、20d和30d后无腹泻和皮肤过敏现象;
(3)本发明的具有降低血脂和体脂功能的益生菌菌群组合物,通过对菌粉进行改性,在冻干保护剂的制备中将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,以及在益生菌菌群组合物中加入改性剂,能够避免中药对益生菌活性的影响,制备的益生菌菌群组合物中益生菌总数量为2.7×1010-3.0×1010cfu/g,在温度为2℃下避光保存10d后,益生菌菌群组合物中益生菌总数量为2.5×1010-2.8×1010cfu/g;
(4)本发明的具有降低血脂和体脂功能的益生菌菌群组合物,通过对菌粉进行改性,在冻干保护剂的制备中将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,以及在益生菌菌群组合物中加入改性剂,能够对益生菌进行改性,从而避免对益生菌产生依赖,在健康成年雄性sd大鼠上做实验,停用益生菌20d后血清TC为1.24-1.29mmol/L,停用益生菌20d后血清TG为0.61-0.63mmol/L,停用益生菌20d后血清LDL-C为0.18-0.19mmol/L,停用益生菌20d后血清HDL-C为1.10-1.12mmol/L,停用益生菌20d后脂体比为0.0135-0.0138。
具体实施方式
为了对本发明的技术特征、目的和效果有更加清楚的理解,现说明本发明的具体实施方式。
实施例1
一种具有降低血脂和体脂功能的益生菌菌群组合物,按重量份计,由以下成分组成:75份改性菌粉,10份中药微胶囊,3份冻干保护剂,6份改性剂。
所述改性菌粉的制备方法,由以下步骤组成:制备种子液、制备发酵液、干燥、改性;
所述制备种子液的方法为:分别将冷冻保存的植物乳杆菌、鼠李糖乳杆菌、副干酪乳杆菌、动物双歧杆菌、两歧双歧杆菌、罗伊氏乳杆菌在固体LB平板上划线进行活化,然后分别从LB平板中挑选单菌落接种于装有100mL液体培养基的250mL锥形瓶中,将250mL锥形瓶放入摇床进行摇床培养,控制摇床培养的温度为36℃,转速为220rpm,时间为12h,摇床培养结束后分别得到植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液;
所述液体培养基,由以下成分组成:3g/L葡萄糖,2g/L胰蛋白胨,0.5g/L红糖,0.3g/L磷酸氢二钠,0.2g/L磷酸二氢钠,剩余为去离子水。
所述制备发酵液的方法为:分别将植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液依次接种于同一MRS液体培养基中,控制植物乳杆菌的接种量为1%,鼠李糖乳杆菌的接种量为1.5%,副干酪乳杆菌的接种量为1.5%,动物双歧杆菌的接种量为2%,两歧双歧杆菌的接种量为2%,罗伊氏乳杆菌的接种量为0.5%,接种完成后进行搅拌发酵培养,控制搅拌发酵培养的温度为36℃,转速为320rpm,通气量为1.5vvm,时间为18h,搅拌发酵培养结束得到发酵液;
所述MRS液体培养基,由以下成分组成:4g/L胰蛋白胨,5g/L葡萄糖,4g/L酵母膏,1.5g/L牛肉膏,1g/L吐温80,0.8g/L磷酸氢二钾,0.3g/L硫酸镁,剩余为去离子水。
所述干燥的方法为:对发酵液进行离心分离,控制离心分离时的转速为2800rpm,时间为5min,离心分离结束后得到的固相物作为菌泥,对菌泥进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-40℃,真空度为400Pa,处理时间为50min,真空冷冻干燥结束得到菌粉。
所述改性的方法为:将菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖混合均匀后,得到初级改性菌粉,将初级改性菌粉置于反应容器内,将反应容器内的温度控制到15℃,搅拌速度控制到100rpm,将改性液雾化后通入反应容器内,控制雾化速度为140g/min,雾化结束后继续搅拌12min,然后进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-35℃,真空度为300Pa,处理时间为30min,真空冷冻干燥结束得到改性菌粉;
其中,菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖的重量比为80:5:2:3:2;
所述初级改性菌粉与改性液的重量比为100:3;
所述改性液的组成,按重量份计,包括:20份去离子水,1份氯化钠,1份大豆多糖,0.8份槐糖脂,0.5份硫酸锌;
所述改性菌粉中的益生菌的总数量为3.5×1010cfu/g。
所述中药微胶囊的制备方法为:分别将白芷、连翘、黄芪、党参洗净后烘干,然后分别粉碎至200目,分别得到白芷粉、连翘粉、黄芪粉、党参粉,然后分别将白芷粉、连翘粉、黄芪粉、党参粉按照质量比为10:22:15:8混合均匀后得到混合中药粉,将混合中药粉与去离子水按照重量比为1:15混合均匀后进行超声破壁提取,控制超声破壁提取的声场频率为40kHz,声强为2.55W/cm2,提取时间为1.5h,提取结束得到中药提取液,将中药提取液进行离心分离,控制离心分离时的转速为3000rpm,时间为6min,离心分离结束后得到的液相物作为滤液,将滤液、明胶、海藻酸钠混合后进行冷冻浓缩,控制冷冻浓缩的温度为-15℃,时间为30min,冷冻浓缩结束得到浓缩液,向浓缩液中加入阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖,混合均匀后进行均质,控制均质的转速为4000rpm,均质时间为5min,均质结束得到均质液,将均质液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为600Pa,进口温度为125℃,出口温度为65℃,真空喷雾干燥结束,得到中药微胶囊;
其中,滤液、明胶、海藻酸钠的重量比为55:5:3;
其中,浓缩液、阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖的重量比为50:3:2:4:1。
所述冻干保护剂的制备方法为:将预糊化淀粉、葡萄糖、麦芽糊精、乳糖混合均匀后,置于球磨机中进行球磨,控制球磨时的球料比为12:1,转速为280rpm,时间为40min,球磨结束得到混合粉,将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,控制电磁震荡处理的频率为130kHz,时间为4min,电磁震荡结束,得到冻干保护剂;
其中,预糊化淀粉、葡萄糖、麦芽糊精、乳糖的重量比为15:3:4:2;
其中,混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素的重量比为30:2:2:1。
所述改性剂的组成,按重量份计,由以下成分组成:5份淀粉微球,1份酪蛋白酸钠,0.5份大豆磷脂,0.1份硬脂酰乳酸钙;
所述淀粉微球的制备方法为:将玉米淀粉、环糊精、聚乙烯醇1788、海藻酸丙二醇酯、三偏磷酸钠加入去离子水中,将温度升高至50-55℃,然后开启搅拌并将搅拌速度控制到200rpm,搅拌30min后,停止搅拌,得到初级淀粉液,将初级淀粉液以3℃/min的速度降温至-20℃,在-20℃下静置17min,然后以1.5℃/min的速度升温至32℃,在32℃下进行以200rpm的搅拌速度搅拌15min,然后对初级淀粉液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为300Pa,进口温度为135℃,出口温度为70℃,真空喷雾干燥结束,得到淀粉微球;
其中,玉米淀粉、环糊精、聚乙烯醇1799、海藻酸丙二醇酯、三偏磷酸钠的重量比为20:2:1:2:2。
所述具有降低血脂和体脂功能的益生菌菌群组合物的制备方法为:将改性菌粉、中药微胶囊、冻干保护剂、改性剂混合均匀后进行真空冷冻干燥,控制真空冷冻干燥处理的温度为-35℃,真空度为500Pa,处理时间为40min,真空冷冻干燥结束,得到降低血脂和体脂功能的益生菌菌群组合物。
实施例2
一种具有降低血脂和体脂功能的益生菌菌群组合物,按重量份计,由以下成分组成:77份改性菌粉,11份中药微胶囊,4份冻干保护剂,7份改性剂。
所述改性菌粉的制备方法,由以下步骤组成:制备种子液、制备发酵液、干燥、改性;
所述制备种子液的方法为:分别将冷冻保存的植物乳杆菌、鼠李糖乳杆菌、副干酪乳杆菌、动物双歧杆菌、两歧双歧杆菌、罗伊氏乳杆菌在固体LB平板上划线进行活化,然后分别从LB平板中挑选单菌落接种于装有100mL液体培养基的250mL锥形瓶中,将250mL锥形瓶放入摇床进行摇床培养,控制摇床培养的温度为37℃,转速为230rpm,时间为13h,摇床培养结束后分别得到植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液;
所述液体培养基,由以下成分组成:3.5g/L葡萄糖,2.5g/L胰蛋白胨,0.6g/L红糖,0.4g/L磷酸氢二钠,0.3g/L磷酸二氢钠,剩余为去离子水。
所述制备发酵液的方法为:分别将植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液依次接种于同一MRS液体培养基中,控制植物乳杆菌的接种量为1.2%,鼠李糖乳杆菌的接种量为1.7%,副干酪乳杆菌的接种量为1.7%,动物双歧杆菌的接种量为2.2%,两歧双歧杆菌的接种量为2.2%,罗伊氏乳杆菌的接种量为0.7%,接种完成后进行搅拌发酵培养,控制搅拌发酵培养的温度为37℃,转速为330rpm,通气量为1.6vvm,时间为19h,搅拌发酵培养结束得到发酵液;
所述MRS液体培养基,由以下成分组成:5g/L胰蛋白胨,6g/L葡萄糖,4.5g/L酵母膏,1.7g/L牛肉膏,1.1g/L吐温80,0.9g/L磷酸氢二钾,0.4g/L硫酸镁,剩余为去离子水。
所述干燥的方法为:对发酵液进行离心分离,控制离心分离时的转速为2900rpm,时间为5.5min,离心分离结束后得到的固相物作为菌泥,对菌泥进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-37℃,真空度为450Pa,处理时间为52min,真空冷冻干燥结束得到菌粉。
所述改性的方法为:将菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖混合均匀后,得到初级改性菌粉,将初级改性菌粉置于反应容器内,将反应容器内的温度控制到17℃,搅拌速度控制到110rpm,将改性液雾化后通入反应容器内,控制雾化速度为145g/min,雾化结束后继续搅拌13min,然后进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-32℃,真空度为350Pa,处理时间为32min,真空冷冻干燥结束得到改性菌粉;
其中,菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖的重量比为82:6:3:4:3;
所述初级改性菌粉与改性液的重量比为102:4;
所述改性液的组成,按重量份计,包括:21份去离子水,2份氯化钠,1.2份大豆多糖,0.9份槐糖脂,0.7份硫酸锌;
所述改性菌粉中的益生菌的总数量为3.7×1010cfu/g。
所述中药微胶囊的制备方法为:分别将白芷、连翘、黄芪、党参洗净后烘干,然后分别粉碎至250目,分别得到白芷粉、连翘粉、黄芪粉、党参粉,然后分别将白芷粉、连翘粉、黄芪粉、党参粉按照质量比为11:22.5:16:9混合均匀后得到混合中药粉,将混合中药粉与去离子水按照重量比为1:16混合均匀后进行超声破壁提取,控制超声破壁提取的声场频率为45kHz,声强为2.55W/cm2,提取时间为1.7h,提取结束得到中药提取液,将中药提取液进行离心分离,控制离心分离时的转速为3100rpm,时间为6.5min,离心分离结束后得到的液相物作为滤液,将滤液、明胶、海藻酸钠混合后进行冷冻浓缩,控制冷冻浓缩的温度为-12℃,时间为32min,冷冻浓缩结束得到浓缩液,向浓缩液中加入阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖,混合均匀后进行均质,控制均质的转速为4500rpm,均质时间为5.5min,均质结束得到均质液,将均质液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为650Pa,进口温度为127℃,出口温度为67℃,真空喷雾干燥结束,得到中药微胶囊;
其中,滤液、明胶、海藻酸钠的重量比为57:6:4;
其中,浓缩液、阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖的重量比为52:4:3:5:1.5。
所述冻干保护剂的制备方法为:将预糊化淀粉、葡萄糖、麦芽糊精、乳糖混合均匀后,置于球磨机中进行球磨,控制球磨时的球料比为12-15:1,转速为290rpm,时间为42min,球磨结束得到混合粉,将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,控制电磁震荡处理的频率为140kHz,时间为4.5min,电磁震荡结束,得到冻干保护剂;
其中,预糊化淀粉、葡萄糖、麦芽糊精、乳糖的重量比为16:4:5:2.5;
其中,混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素的重量比为31:3:2.5:1.2。
所述改性剂的组成,按重量份计,由以下成分组成:6份淀粉微球,1.5份酪蛋白酸钠,0.7份大豆磷脂,0.2份硬脂酰乳酸钙;
所述淀粉微球的制备方法为:将玉米淀粉、环糊精、聚乙烯醇1788、海藻酸丙二醇酯、三偏磷酸钠加入去离子水中,将温度升高至52℃,然后开启搅拌并将搅拌速度控制到210rpm,搅拌32min后,停止搅拌,得到初级淀粉液,将初级淀粉液以3.5℃/min的速度降温至-17℃,在-17℃下静置18min,然后以1.7℃/min的速度升温至33℃,在33℃下进行以210rpm的搅拌速度搅拌17min,然后对初级淀粉液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为350Pa,进口温度为137℃,出口温度为72℃,真空喷雾干燥结束,得到淀粉微球;
其中,玉米淀粉、环糊精、聚乙烯醇1799、海藻酸丙二醇酯、三偏磷酸钠的重量比为21:3:2:3:3。
所述具有降低血脂和体脂功能的益生菌菌群组合物的制备方法为:将改性菌粉、中药微胶囊、冻干保护剂、改性剂混合均匀后进行真空冷冻干燥,控制真空冷冻干燥处理的温度为-32℃,真空度为600Pa,处理时间为42min,真空冷冻干燥结束,得到降低血脂和体脂功能的益生菌菌群组合物。
实施例3
一种具有降低血脂和体脂功能的益生菌菌群组合物,按重量份计,由以下成分组成:80份改性菌粉,12份中药微胶囊,5份冻干保护剂,8份改性剂。
所述改性菌粉的制备方法,由以下步骤组成:制备种子液、制备发酵液、干燥、改性;
所述制备种子液的方法为:分别将冷冻保存的植物乳杆菌、鼠李糖乳杆菌、副干酪乳杆菌、动物双歧杆菌、两歧双歧杆菌、罗伊氏乳杆菌在固体LB平板上划线进行活化,然后分别从LB平板中挑选单菌落接种于装有100mL液体培养基的250mL锥形瓶中,将250mL锥形瓶放入摇床进行摇床培养,控制摇床培养的温度为38℃,转速为240rpm,时间为14h,摇床培养结束后分别得到植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液;
所述液体培养基,由以下成分组成:4g/L葡萄糖,3g/L胰蛋白胨,0.7g/L红糖,0.5g/L磷酸氢二钠,0.4g/L磷酸二氢钠,剩余为去离子水。
所述制备发酵液的方法为:分别将植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液依次接种于同一MRS液体培养基中,控制植物乳杆菌的接种量为1.5%,鼠李糖乳杆菌的接种量为2%,副干酪乳杆菌的接种量为2%,动物双歧杆菌的接种量为2.5%,两歧双歧杆菌的接种量为2.5%,罗伊氏乳杆菌的接种量为1%,接种完成后进行搅拌发酵培养,控制搅拌发酵培养的温度为38℃,转速为340rpm,通气量为1.7vvm,时间为20h,搅拌发酵培养结束得到发酵液;
所述MRS液体培养基,由以下成分组成:6g/L胰蛋白胨,7g/L葡萄糖,5g/L酵母膏,2g/L牛肉膏,1.2g/L吐温80,1g/L磷酸氢二钾,0.5g/L硫酸镁,剩余为去离子水。
所述干燥的方法为:对发酵液进行离心分离,控制离心分离时的转速为3000rpm,时间为6min,离心分离结束后得到的固相物作为菌泥,对菌泥进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-35℃,真空度为500Pa,处理时间为55min,真空冷冻干燥结束得到菌粉。
所述改性的方法为:将菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖混合均匀后,得到初级改性菌粉,将初级改性菌粉置于反应容器内,将反应容器内的温度控制到20℃,搅拌速度控制到120rpm,将改性液雾化后通入反应容器内,控制雾化速度为150g/min,雾化结束后继续搅拌15min,然后进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-30℃,真空度为400Pa,处理时间为35min,真空冷冻干燥结束得到改性菌粉;
其中,菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖的重量比为85:7:4:6:5;
所述初级改性菌粉与改性液的重量比为105:5;
所述改性液的组成,按重量份计,包括:22份去离子水,3份氯化钠,1.5份大豆多糖,1份槐糖脂,0.8份硫酸锌;
所述改性菌粉中的益生菌的总数量为4.0×1010cfu/g。
所述中药微胶囊的制备方法为:分别将白芷、连翘、黄芪、党参洗净后烘干,然后分别粉碎至300目,分别得到白芷粉、连翘粉、黄芪粉、党参粉,然后分别将白芷粉、连翘粉、黄芪粉、党参粉按照质量比为12:23:17:10混合均匀后得到混合中药粉,将混合中药粉与去离子水按照重量比为1:17混合均匀后进行超声破壁提取,控制超声破壁提取的声场频率为50kHz,声强为2.55W/cm2,提取时间为2h,提取结束得到中药提取液,将中药提取液进行离心分离,控制离心分离时的转速为3200rpm,时间为7min,离心分离结束后得到的液相物作为滤液,将滤液、明胶、海藻酸钠混合后进行冷冻浓缩,控制冷冻浓缩的温度为-10℃,时间为35min,冷冻浓缩结束得到浓缩液,向浓缩液中加入阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖,混合均匀后进行均质,控制均质的转速为5000rpm,均质时间为6min,均质结束得到均质液,将均质液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为700Pa,进口温度为130℃,出口温度为70℃,真空喷雾干燥结束,得到中药微胶囊;
其中,滤液、明胶、海藻酸钠的重量比为60:7:5;
其中,浓缩液、阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖的重量比为55:5:4:6:2。
所述冻干保护剂的制备方法为:将预糊化淀粉、葡萄糖、麦芽糊精、乳糖混合均匀后,置于球磨机中进行球磨,控制球磨时的球料比为15:1,转速为300rpm,时间为45min,球磨结束得到混合粉,将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,控制电磁震荡处理的频率为150kHz,时间为5min,电磁震荡结束,得到冻干保护剂;
其中,预糊化淀粉、葡萄糖、麦芽糊精、乳糖的重量比为18:5:6:3;
其中,混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素的重量比为32:4:3:1.5。
所述改性剂的组成,按重量份计,由以下成分组成:7份淀粉微球,2份酪蛋白酸钠,0.8份大豆磷脂,0.3份硬脂酰乳酸钙;
所述淀粉微球的制备方法为:将玉米淀粉、环糊精、聚乙烯醇1788、海藻酸丙二醇酯、三偏磷酸钠加入去离子水中,将温度升高至55℃,然后开启搅拌并将搅拌速度控制到220rpm,搅拌35min后,停止搅拌,得到初级淀粉液,将初级淀粉液以4℃/min的速度降温至-15℃,在-15℃下静置20min,然后以2℃/min的速度升温至35℃,在35℃下进行以220rpm的搅拌速度搅拌20min,然后对初级淀粉液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为400Pa,进口温度为140℃,出口温度为75℃,真空喷雾干燥结束,得到淀粉微球;
其中,玉米淀粉、环糊精、聚乙烯醇1799、海藻酸丙二醇酯、三偏磷酸钠的重量比为22:4:3:5:4。
所述具有降低血脂和体脂功能的益生菌菌群组合物的制备方法为:将改性菌粉、中药微胶囊、冻干保护剂、改性剂混合均匀后进行真空冷冻干燥,控制真空冷冻干燥处理的温度为-30℃,真空度为700Pa,处理时间为45min,真空冷冻干燥结束,得到降低血脂和体脂功能的益生菌菌群组合物。
对比例1
采用实施例1所述的技术方案,其不同之处在于:改性菌粉的制备中省略改性步骤。
对比例2
采用实施例1所述的技术方案,其不同之处在于:冻干保护剂的制备中省略将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理步骤,即将冻干保护剂的制备中的混合粉作为冻干保护剂使用。
对比例3
采用实施例1所述的技术方案,其不同之处在于:具有降低血脂和体脂功能的益生菌菌群组合物的组成和制备中省略改性剂的加入。
试验例1
将实施例1-3和对比例1-3的具有降低血脂和体脂功能的益生菌菌群组合物进行小鼠试验,试验方法及结果如下:
选择120只8周龄,体重为200±10g的健康成年雄性sd大鼠,平分为6组,编号A1-A6组,每组20只,均饲喂于同一动物房,保证动物房内的温度为24±2℃,湿度为60±2%,动物自由进食,每组小鼠所进食的饲料相同,进行7d适应性饲养后,向饲料中添加蔗糖、猪油、胆固醇、胆酸钠后混合均匀,得到加脂饲料,控制加脂饲料中蔗糖的质量分数为20%,猪油的质量分数为15%,胆固醇的质量分数为1.2%,胆酸钠的质量分数为0.2%,使用加脂饲料对每组小鼠进行继续喂食,喂食20d后,对每只小鼠进行称重作为食用益生菌前的体重,然后计算每组的平均体重作为食用益生菌前的平均体重;然后每组随机挑选1只小鼠麻醉,解剖取肾周围脂肪、睾丸周围脂肪,并称重,计算并记录脂/体比,再从每组随机挑选5只小鼠,对挑选出的5只小鼠标记后进行不禁食采血(眼内眦或尾部),采血后尽快分离血清,测定并记录血清TC、TG、LDL-C、HDL-C水平,并计算每组的平均值,作为食用益生菌前的TC、TG、LDL-C、HDL-C水平;
然后停止使用食用加脂饲料,改用未添加蔗糖、猪油、胆固醇、胆酸钠的饲料继续进行喂养,同时分别对每组小鼠喂养实施例1-3和对比例1-3的具有降低血脂和体脂功能的益生菌菌群组合物,控制每只小鼠每天喂养0.3g益生菌菌群组合物,每组小鼠与益生菌的对应关系如下:
连续喂养益生菌菌群组合物10天后,分别对每只小鼠进行称重作为食用10d益生菌后的体重,然后计算每组平均体重作为食用益生菌10d后的平均体重;然后每组随机挑选1只小鼠麻醉,解剖取肾周围脂肪、睾丸周围脂肪,并称重,计算并记录脂/体比,再对每组做标记的5只小鼠标记后进行不禁食采血(眼内眦或尾部),采血后尽快分离血清,测定并记录血清TC、TG、LDL-C、HDL-C水平,并计算每组的平均值,作为食用益生菌10d后的TC、TG、LDL-C、HDL-C水平,同时观察每组小鼠是否存在腹泻和皮肤过敏现象;
连续喂养益生菌菌群组合物20天后,分别对每只小鼠进行称重作为食用20d益生菌后的体重,然后计算每组平均体重作为食用益生菌20d后的平均体重;然后每组随机挑选1只小鼠麻醉,解剖取肾周围脂肪、睾丸周围脂肪,并称重,计算并记录脂/体比,再对每组做标记的5只小鼠标记后进行不禁食采血(眼内眦或尾部),采血后尽快分离血清,测定并记录血清TC、TG、LDL-C、HDL-C水平,并计算每组的平均值,作为食用益生菌20d后的TC、TG、LDL-C、HDL-C水平,同时观察每组小鼠是否存在腹泻和皮肤过敏现象;
连续喂养益生菌菌群组合物30天后,分别对每只小鼠进行称重作为食用30d益生菌后的体重,然后计算每组平均体重作为食用益生菌30d后的平均体重;然后每组随机挑选1只小鼠麻醉,解剖取肾周围脂肪、睾丸周围脂肪,并称重,计算并记录脂/体比,再对每组做标记的5只小鼠标记后进行不禁食采血(眼内眦或尾部),采血后尽快分离血清,测定并记录血清TC、TG、LDL-C、HDL-C水平,并计算每组的平均值,作为食用益生菌30d后的TC、TG、LDL-C、HDL-C水平,同时观察每组小鼠是否存在腹泻和皮肤过敏现象;
脂体比的计算公式为:(肾周脂肪垫+附睾脂肪垫)/体重×100%;
计算及测试结果如下:
然后继续喂养20d,每组小鼠均不使用益生菌,且使用未添加蔗糖、猪油、胆固醇、胆酸钠的饲料进行喂养,最后对每只小鼠进行称重,并计算每组的平均体重作为停用益生菌20d后的平均体重;再对每组做标记的5只小鼠标记后进行不禁食采血(眼内眦或尾部),采血后尽快分离血清,测定并记录血清TC、TG、LDL-C、HDL-C水平,并计算每组的平均值,作为停用益生菌20d后的TC、TG、LDL-C、HDL-C水平;计算结果如下:
试验例2
分别对实施例1-3和对比例1-3的具有降低血脂和体脂功能的益生菌菌群组合物中的益生菌的总数量进行检测,作为避光保存前的益生菌总数量,然后在温度为2℃下避光保存10d后,分别对益生菌菌群组合物中的益生菌的总数量进行检测,作为避光保存后的益生菌总数量,检测结果如下:
除非另有说明,本发明中所采用的百分数均为质量百分数。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种具有降低血脂和体脂功能的益生菌菌群组合物,其特征在于,按重量份计,由以下成分组成:75-80份改性菌粉,10-12份中药微胶囊,3-5份冻干保护剂,6-8份改性剂;
所述改性菌粉的制备方法,由以下步骤组成:制备种子液、制备发酵液、干燥、改性;
所述改性的方法为:将菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖混合均匀后,得到初级改性菌粉,将初级改性菌粉置于反应容器内,将反应容器内的温度控制到15-20℃,搅拌速度控制到100-120rpm,将改性液雾化后通入反应容器内,控制雾化速度为140-150g/min,雾化结束后继续搅拌12-15min,然后进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-35℃至-30℃,真空度为300-400Pa,处理时间为30-35min,真空冷冻干燥结束得到改性菌粉;
所述改性中,菌粉、葡甘聚糖、刺槐豆胶、盐藻多糖、水苏糖的重量比为80-85:5-7:2-4:3-6:2-5;
所述改性中,所述初级改性菌粉与改性液的重量比为100-105:3-5;
所述改性中,所述改性液的组成,按重量份计,包括:20-22份去离子水,1-3份氯化钠,1-1.5份大豆多糖,0.8-1份槐糖脂,0.5-0.8份硫酸锌;
所述改性菌粉中的益生菌的总数量为3.5×1010-4.0×1010cfu/g;
所述中药微胶囊的制备方法为:分别将白芷、连翘、黄芪、党参洗净后烘干,然后分别粉碎至200-300目,分别得到白芷粉、连翘粉、黄芪粉、党参粉,然后分别将白芷粉、连翘粉、黄芪粉、党参粉按照质量比为10-12:22-23:15-17:8-10混合均匀后得到混合中药粉,将混合中药粉与去离子水按照重量比为1:15-17混合均匀后进行超声破壁提取,控制超声破壁提取的声场频率为40-50kHz,声强为2.55W/cm2,提取时间为1.5-2h,提取结束得到中药提取液,将中药提取液进行离心分离,控制离心分离时的转速为3000-3200rpm,时间为6-7min,离心分离结束后得到的液相物作为滤液,将滤液、明胶、海藻酸钠混合后进行冷冻浓缩,控制冷冻浓缩的温度为-15℃至-10℃,时间为30-35min,冷冻浓缩结束得到浓缩液,向浓缩液中加入阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖,混合均匀后进行均质,控制均质的转速为4000-5000rpm,均质时间为5-6min,均质结束得到均质液,将均质液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为600-700Pa,进口温度为125-130℃,出口温度为65-70℃,真空喷雾干燥结束,得到中药微胶囊;
所述中药微胶囊的制备中,滤液、明胶、海藻酸钠的重量比为55-60:5-7:3-5;
所述中药微胶囊的制备中,浓缩液、阿拉伯胶、麦芽糊精、三聚甘油单硬脂酸酯、低聚木糖的重量比为50-55:3-5:2-4:4-6:1-2;
所述冻干保护剂的制备方法为:将预糊化淀粉、葡萄糖、麦芽糊精、乳糖混合均匀后,置于球磨机中进行球磨,控制球磨时的球料比为12-15:1,转速为280-300rpm,时间为40-45min,球磨结束得到混合粉,将混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素混合后进行电磁震荡处理,控制电磁震荡处理的频率为130-150kHz,时间为4-5min,电磁震荡结束,得到冻干保护剂;
所述冻干保护剂的制备中,预糊化淀粉、葡萄糖、麦芽糊精、乳糖的重量比为15-18:3-5:4-6:2-3;
所述冻干保护剂的制备中,混合粉、柠檬酸、聚乙烯吡咯烷酮、茶皂素的重量比为30-32:2-4:2-3:1-1.5;
所述改性剂的组成,按重量份计,由以下成分组成:5-7份淀粉微球,1-2份酪蛋白酸钠,0.5-0.8份大豆磷脂,0.1-0.3份硬脂酰乳酸钙;
所述淀粉微球的制备方法为:将玉米淀粉、环糊精、聚乙烯醇1788、海藻酸丙二醇酯、三偏磷酸钠加入去离子水中,将温度升高至50-55℃,然后开启搅拌并将搅拌速度控制到200-220rpm,搅拌30-35min后,停止搅拌,得到初级淀粉液,将初级淀粉液以3-4℃/min的速度降温至-20℃至-15℃,在-20℃至-15℃下静置17-20min,然后以1.5-2℃/min的速度升温至32-35℃,在32-35℃下进行以200-220rpm的搅拌速度搅拌15-20min,然后对初级淀粉液进行真空喷雾干燥,控制真空喷雾干燥中的真空度为300-400Pa,进口温度为135-140℃,出口温度为70-75℃,真空喷雾干燥结束,得到淀粉微球;
所述淀粉微球的制备中,玉米淀粉、环糊精、聚乙烯醇1799、海藻酸丙二醇酯、三偏磷酸钠的重量比为20-22:2-4:1-3:2-5:2-4。
2.根据权利要求1所述的具有降低血脂和体脂功能的益生菌菌群组合物,其特征在于,所述制备种子液的方法为:分别将冷冻保存的植物乳杆菌、鼠李糖乳杆菌、副干酪乳杆菌、动物双歧杆菌、两歧双歧杆菌、罗伊氏乳杆菌在固体LB平板上划线进行活化,然后分别从LB平板中挑选单菌落接种于装有100mL液体培养基的250mL锥形瓶中,将250mL锥形瓶放入摇床进行摇床培养,控制摇床培养的温度为36-38℃,转速为220-240rpm,时间为12-14h,摇床培养结束后分别得到植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液;
所述液体培养基,由以下成分组成:3-4g/L葡萄糖,2-3g/L胰蛋白胨,0.5-0.7g/L红糖,0.3-0.5g/L磷酸氢二钠,0.2-0.4g/L磷酸二氢钠,剩余为去离子水。
3.根据权利要求1所述的具有降低血脂和体脂功能的益生菌菌群组合物,其特征在于,所述制备发酵液的方法为:分别将植物乳杆菌种子液、鼠李糖乳杆菌种子液、副干酪乳杆菌种子液、动物双歧杆菌种子液、两歧双歧杆菌种子液、罗伊氏乳杆菌种子液依次接种于同一MRS液体培养基中,控制植物乳杆菌的接种量为1-1.5%,鼠李糖乳杆菌的接种量为1.5-2%,副干酪乳杆菌的接种量为1.5-2%,动物双歧杆菌的接种量为2-2.5%,两歧双歧杆菌的接种量为2-2.5%,罗伊氏乳杆菌的接种量为0.5-1%,接种完成后进行搅拌发酵培养,控制搅拌发酵培养的温度为36-38℃,转速为320-340rpm,通气量为1.5-1.7vvm,时间为18-20h,搅拌发酵培养结束得到发酵液;
所述MRS液体培养基,由以下成分组成:4-6g/L胰蛋白胨,5-7g/L葡萄糖,4-5g/L酵母膏,1.5-2g/L牛肉膏,1-1.2g/L吐温80,0.8-1g/L磷酸氢二钾,0.3-0.5g/L硫酸镁,剩余为去离子水。
4.根据权利要求1所述的具有降低血脂和体脂功能的益生菌菌群组合物,其特征在于,所述干燥的方法为:对发酵液进行离心分离,控制离心分离时的转速为2800-3000rpm,时间为5-6min,离心分离结束后得到的固相物作为菌泥,对菌泥进行真空冷冻干燥处理,控制真空冷冻干燥处理的温度为-40℃至-35℃,真空度为400-500Pa,处理时间为50-55min,真空冷冻干燥结束得到菌粉。
5.根据权利要求1所述的具有降低血脂和体脂功能的益生菌菌群组合物,其特征在于,所述具有降低血脂和体脂功能的益生菌菌群组合物的制备方法为:将改性菌粉、中药微胶囊、冻干保护剂、改性剂混合均匀后进行真空冷冻干燥,控制真空冷冻干燥处理的温度为-35℃至-30℃,真空度为500-700Pa,处理时间为40-45min,真空冷冻干燥结束,得到降低血脂和体脂功能的益生菌菌群组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210958232.2A CN115153029A (zh) | 2022-08-11 | 2022-08-11 | 一种具有降低血脂和体脂功能的益生菌菌群组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210958232.2A CN115153029A (zh) | 2022-08-11 | 2022-08-11 | 一种具有降低血脂和体脂功能的益生菌菌群组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115153029A true CN115153029A (zh) | 2022-10-11 |
Family
ID=83480327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210958232.2A Pending CN115153029A (zh) | 2022-08-11 | 2022-08-11 | 一种具有降低血脂和体脂功能的益生菌菌群组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115153029A (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008035332A1 (en) * | 2006-09-19 | 2008-03-27 | Technion Research And Development Foundation Ltd. | Probiotic compositions and methods of making same |
CN104473183A (zh) * | 2014-11-30 | 2015-04-01 | 邵素英 | 一种减肥益生菌片剂及其制备方法 |
WO2015172191A1 (en) * | 2014-05-12 | 2015-11-19 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
CN105685972A (zh) * | 2016-02-02 | 2016-06-22 | 武汉万德瑞生物技术有限公司 | 具有减脂瘦身功能的益生菌组合物及其制备方法与应用 |
CN109105902A (zh) * | 2018-09-03 | 2019-01-01 | 上海珂鑫生物技术有限公司 | 一种用于减肥的复合益生菌制剂及其应用方法 |
WO2020243705A1 (en) * | 2019-05-30 | 2020-12-03 | New York University | Probiotic compositions and methods of use |
CN112826855A (zh) * | 2021-01-04 | 2021-05-25 | 刘�文 | 一种中药与益生菌复合增效的降脂溶栓制剂及其制备方法 |
CN113662996A (zh) * | 2021-08-25 | 2021-11-19 | 广州市沐家健康产业有限公司 | 具有减肥作用的益生菌组合物及其制备方法 |
CN114699477A (zh) * | 2022-06-08 | 2022-07-05 | 源民生物科技(山东)有限公司 | 一种具有安神助眠功能的益生菌群组合物 |
CN114712406A (zh) * | 2022-06-08 | 2022-07-08 | 源民生物科技(山东)有限公司 | 一种具有预防皮肤衰老功能的益生菌群组合物 |
-
2022
- 2022-08-11 CN CN202210958232.2A patent/CN115153029A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008035332A1 (en) * | 2006-09-19 | 2008-03-27 | Technion Research And Development Foundation Ltd. | Probiotic compositions and methods of making same |
WO2015172191A1 (en) * | 2014-05-12 | 2015-11-19 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
CN104473183A (zh) * | 2014-11-30 | 2015-04-01 | 邵素英 | 一种减肥益生菌片剂及其制备方法 |
CN105685972A (zh) * | 2016-02-02 | 2016-06-22 | 武汉万德瑞生物技术有限公司 | 具有减脂瘦身功能的益生菌组合物及其制备方法与应用 |
CN109105902A (zh) * | 2018-09-03 | 2019-01-01 | 上海珂鑫生物技术有限公司 | 一种用于减肥的复合益生菌制剂及其应用方法 |
WO2020243705A1 (en) * | 2019-05-30 | 2020-12-03 | New York University | Probiotic compositions and methods of use |
CN112826855A (zh) * | 2021-01-04 | 2021-05-25 | 刘�文 | 一种中药与益生菌复合增效的降脂溶栓制剂及其制备方法 |
CN113662996A (zh) * | 2021-08-25 | 2021-11-19 | 广州市沐家健康产业有限公司 | 具有减肥作用的益生菌组合物及其制备方法 |
CN114699477A (zh) * | 2022-06-08 | 2022-07-05 | 源民生物科技(山东)有限公司 | 一种具有安神助眠功能的益生菌群组合物 |
CN114712406A (zh) * | 2022-06-08 | 2022-07-08 | 源民生物科技(山东)有限公司 | 一种具有预防皮肤衰老功能的益生菌群组合物 |
Non-Patent Citations (4)
Title |
---|
吕嘉枥等: "十株益生菌发酵液降脂能力研究", 《陕西科技大学学报》 * |
梅全喜: "《现代中药药理与临床应用手册 第三版》", 31 October 2016, 中国中医药出版社 * |
蔡向红: "《本草纲目方药精选》", 31 May 2017, 陕西科学技术出版社 * |
郭力,李廷俊: "《高脂血症预防与调养》", 30 September 2016, 中国中医药出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102366024B (zh) | 一种含中药活性益生菌的猪饲料添加剂的制造方法 | |
CN108208853A (zh) | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 | |
CN101760478A (zh) | 一种葛根红曲的制造方法 | |
CN104855845A (zh) | 一种纳豆营养健康食品 | |
CN106722206A (zh) | 一种缓解消化道不适症状和/或情绪压力的组合物及其产品 | |
CN106420847A (zh) | 辅助保护胃黏膜和/或缓解胃胀的组合物及其微生态制剂 | |
CN111213885A (zh) | 一种具有调节血脂功效的益生菌组合物及其制备方法与应用 | |
CN103110861A (zh) | 一种预防婴幼儿上火调节肠胃的颗粒剂及其制备方法 | |
CN108785331A (zh) | 一种具有气血双补的组合物及其制备方法和应用 | |
CN107693699A (zh) | 一种提高人体免疫力的中药制剂及制备方法 | |
CN106177885B (zh) | 一种用于健胃补脾的复方发酵中药制剂及其制备方法 | |
CN105535650A (zh) | 具有抗肿瘤功能的益生菌组合物及其制备方法与应用 | |
CN105030950B (zh) | 防治高血脂的微生态制剂及其制备方法和应用 | |
CN105768106A (zh) | 一种有助于肝营养改善的功能性食品 | |
CN111329055B (zh) | 一种簕菜酵素的制备方法 | |
CN106173326A (zh) | 一种奶牛用中草药益生菌复合生物制剂及其制备方法 | |
WO2020057451A1 (zh) | 治疗脱发组合物的制备方法 | |
CN109010662A (zh) | 一种促消化促生长微生态制剂及其制备方法 | |
CN113424965A (zh) | 一种更适合黄种人群的微生态制剂 | |
CN109527099A (zh) | 一种枸杞复合益生菌羊奶片及其制备方法 | |
CN112603953A (zh) | 一种减肥降脂外用组合物及其制备方法 | |
CN115153029A (zh) | 一种具有降低血脂和体脂功能的益生菌菌群组合物 | |
CN114146120B (zh) | 一种预防及治疗萎缩性胃炎的组合物微胶囊及其制备方法 | |
CN109043259A (zh) | 一种酵素l-阿拉伯糖水苏糖复合饮料浓浆 | |
CN111603489A (zh) | 一种改善便秘的菌剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |